Carmustine
- Generic Name
- Carmustine
- Brand Names
- Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9Cl2N3O2
- CAS Number
- 154-93-8
- Unique Ingredient Identifier
- U68WG3173Y
- Background
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...
- Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
- Associated Conditions
- Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
- Conditions
- First Posted Date
- 2003-04-30
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- Darell D. Bigner, MD, PhD
- Target Recruit Count
- 21
- Registration Number
- NCT00003484
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
- Conditions
- First Posted Date
- 2003-04-25
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT00003346
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Lymphoma
- Conditions
- Interventions
- Biological: Filgrastim (G-CSF)Biological: Bleomycin Sulfate (BLM)Biological: Recombinant Interferon AlfaDrug: CarmustineDrug: Cytarabine (ARA-C)Drug: Cisplatin (CDDP)Drug: Etoposide (VP-16)Drug: CyclophosphamideDrug: IfosfamideDrug: IdarubicinDrug: MelphalanDrug: Leucovorin CalciumDrug: mitoxantrone hydrochloride (DHAD)Drug: MethotrexateProcedure: Peripheral Blood Stem Cell TransplantationDrug: MethylprednisoloneDrug: Vincristine SulfateRadiation: Radiation Therapy
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT00002835
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2003-04-10
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 1000
- Registration Number
- NCT00002653
- Locations
- 🇬🇧
MRC Myelomatosis Trials Office, Birmingham, England, United Kingdom
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 44
- Registration Number
- NCT00058292
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 312
- Registration Number
- NCT00002556
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005637
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 36
- Registration Number
- NCT00002986
- Locations
- 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00005961
- Locations
- 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸Evanston Northwestern Health Care, Evanston, Illinois, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002982
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.